These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
Muscular Dystrophy UK and Healx announce partnership to identify FSHD treatments
MDUK and Healx announce new partnership to identify FSHD treatments
Read more-
FSHD drug granted orphan drug status by FDA
29/01/2020Fulcrum Therapeutics has announced that the FDA has granted Orphan Drug designation to losmapimod for the treatment of patients with FSHD in the USA.
-
Real-world data study in FSHD
15/10/2019Facio Therapies has announced the completion of a ‘real-world data’ study monitoring the progression of FSHD and its impact on daily life.
-
Acceleron stop development of ACE-083 for FSHD
17/09/2019Acceleron Pharma has announced topline results from its phase 2 trial testing ACE-083 in adults with facioscapulohumeral muscular dystrophy (FSHD).
-
£1.2m invested in 9 new research projects for 2019
02/09/2019Muscular Dystrophy UK is investing £1.2 million into 9 new research projects this year, bringing our total research portfolio to over £10m.
-
Scientists make ground-breaking discovery on FSHD gene
19/07/2019Scientists from Fred Hutchinson Cancer Research Center (USA) have identified a new role for DUX4, the gene that is mutated in FSHD
-
Highlights from the 2019 FSH Society International Research Congress
15/07/2019The FSH Society International Research Congress was held in France, on 19-20 June 2019
-
Fulcrum repurpose drug for FSHD
24/04/2019Fulcrum Therapeutics has obtained rights to losmapimod from GSK. Fulcrum is interested in the drug because it has found that it can switch off DUX4 in FSHD cells.
-
Update from FSHD drug screening programme
21/03/2019Facio Therapies announced today that it has completed a comprehensive search for new FSHD drug candidates.
-
New FSHD mouse model treated with gene therapy
26/11/2018A recent study has demonstrated the value of a new mouse model of facioscapulohumeral muscular dystrophy (FSHD).
-
Update on FSHD drug development programme
01/11/2018Facio Therapies has shown that one of its lead compounds can reduce the levels of DUX4 in a mouse model.